platelet-poor plasma (Regenexx)

Platelet-poor plasma (PPP) is an autologous blood-derived biologic product characterized by a significantly lower concentration of platelets (typically less than 50,000/µL) compared to whole blood or platelet-rich plasma (PRP). It is produced through the centrifugation of anticoagulated whole blood, which separates the plasma fraction from the platelet-rich buffy coat and red blood cells. While historically considered a byproduct of PRP preparation, PPP contains essential plasma proteins such as fibrinogen, albumin, and fibronectin, as well as baseline levels of various growth factors and cytokines. In clinical settings, PPP is utilized for its potential to modulate the inflammatory microenvironment, serve as a biological scaffold or sealant, and promote tissue healing. It is being investigated for applications in thoracic surgery to reduce post-operative air leaks, in orthopedics for the treatment of degenerative disc disease and axial back pain, and as a joint lavage for osteoarthritis to alter catabolic marker levels.

Other names

PPPconcentrated platelet-poor plasmaPPPcautologous platelet-poor plasma